TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$86.25 Million

Vera Therapeutics, Inc.

Initial Public Offering

Bookrunner, April 2021

Vera Therapeutics, Inc.

Vera Therapeutics is a clinical stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Their lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Vera is conducting a Phase 2b clinical trial of atacicept in patients with immunoglobulin A nephropathy (IgAN), a disease with a high unmet medical need and no approved therapies. In addition, Vera is evaluating additional diseases where atacicept’s reduction of autoantibodies may prove medically useful, including lupus nephritis (LN), a severe renal manifestation of systemic lupus erythematosus (SLE).